Drugs that contain Ripretinib
1. List of Qinlock drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8188113 | DECIPHERA PHARMS | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jul, 2030
(7 years from now) | |
| US8461179 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48731 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(9 years from now) | |
| US11266635 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
| US10966966 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
| US11433056 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
| US11344536 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
| US11426390 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
| US11185535 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(17 years from now) | |
| US11395818 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 15, 2025 |
| Orphan Drug Exclusivity (ODE) | May 15, 2027 |
NCE-1 date: May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumor; Treatment of gastrointestinal stromal tumors in patients suffering from palmer-planter erythrodysesthesia syndrome; Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib; Method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily; Treatment of gastrointestinal stromal tumors in patients suffering from hypertension; Treatment of gastrointestinal stromal tumors in patients being treated concurrently with a cyp3a4 inhibitor
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic